Cardiff Oncology, Inc.CRDFNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank43
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-3.81
↓ 22% vs avg
Percentile
P43
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-3.13
Historical baseline
PeriodValueYoY Change
2025-3.81-17.1%
2024-3.25-213.9%
2023-1.04+13.4%
2022-1.20+85.0%
2021-7.95+39.0%
2020-13.03-19642.0%
20190.07-74.1%
20180.26+252.4%
2017-0.17+85.2%
2016-1.14-